Recruiting
A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes.
I8B-MC-ITSZ - ClinicalTrials.gov - NCT04585776
The reason for this study is to evaluate the amount of time with glucose values within target range.
How long will I be in the trial?
The study will last about 74 days and may include up to 15 visits.
Recruiting
A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes.
I8B-MC-ITSZ - ClinicalTrials.gov - NCT04585776
The reason for this study is to evaluate the amount of time with glucose values within target range.
How long will I be in the trial?
The study will last about 74 days and may include up to 15 visits.
Key Requirements
Age :
18-65
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18-65
Sex
All
Participants must
Participants must have type 1 diabetes and have been treated with insulin therapy for at least 1 year
Participants must be using Dexcom G5 or G6 Continuous Glucose Monitoring (CGM) and with a total CGM use ≥ 6 months in the prior year
Participants must have been on the same type of short acting insulin (Humalog U-100 or Novolog) for at least 30 days prior to screening
Participants must have been treated with long-acting insulin degludec U-100 for at least 30 days prior to screening
Participants must NOT
Participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months before screening
Participants must not have had more than 1 episode of severe hypoglycemia within the last 90 days prior to screening
Participants must not be taking certain diabetes medications that are not allowed for study participation
Trial Summary
Conditions the trial is for
Type 1 Diabetes
What the trial is testing?
LY9000014, Insulin Degludec
Could I receive a Placebo?
no
Enrollment Goal
34
Trial Dates
October 2020 - March 2021
Trial Phase
2
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18-65
Sex
All
Participants must
Participants must have type 1 diabetes and have been treated with insulin therapy for at least 1 year
Participants must be using Dexcom G5 or G6 Continuous Glucose Monitoring (CGM) and with a total CGM use ≥ 6 months in the prior year
Participants must have been on the same type of short acting insulin (Humalog U-100 or Novolog) for at least 30 days prior to screening
Participants must have been treated with long-acting insulin degludec U-100 for at least 30 days prior to screening
Participants must NOT
Participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months before screening
Participants must not have had more than 1 episode of severe hypoglycemia within the last 90 days prior to screening
Participants must not be taking certain diabetes medications that are not allowed for study participation
Trial Summary
Conditions the trial is for
Type 1 Diabetes
What the trial is testing?
LY9000014, Insulin Degludec
Could I receive a Placebo?
no
Enrollment Goal
34
Trial Dates
October 2020 - March 2021
Trial Phase
2
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Type 1 Diabetes Resources
